Valuation check: IRIX's profit margin is -6.23%, below the Healthcare sector average of 15.58%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
The latest profit margin for IRIX is -6.23% as of March 2026. That compares with -14.61% in the prior-year period — up 57.4% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside IRIDEX's historical trend and sector peers before judging valuation or financial health.
Over the past year, IRIX's profit margin moved from -14.61% to -6.23% — a 57.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in IRIDEX's valuation or profitability profile.
Against Healthcare companies, IRIX currently prints -6.23% for profit margin, while the sector average sits near 15.58%. That is roughly 140.0% below the sector mean. Large gaps often invite a closer look at IRIDEX's growth, margins, and balance sheet.
Profit Margin shows how effectively IRIDEX converts resources into returns. At -6.23%, IRIX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -14.61% in the prior-year period — up 57.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IRIX's profit margin (-6.23%), review year-over-year change from -14.61%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.